(Q42868390)

8 November 2017

title

The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients (English)

1 reference

8 November 2017

The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer Patients (English)

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

28 July 2024

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

Palle Lyngsie Pedersen

2

object named as

P. Pedersen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20926004

28 July 2024

author name string

M. H. Kristensen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20926004

28 July 2024

J. Mejer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20926004

28 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20926004

28 July 2024

publication date

1 July 2010

1 reference

full work available at URL

8 November 2017

http://journals.sagepub.com/doi/pdf/10.1177/147323001003800413

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Journal of International Medical Research

28 July 2024

published in

1 reference

8 November 2017

volume

38

1 reference

8 November 2017

issue

4

1 reference

8 November 2017

page(s)

1313-1323

1 reference

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Capecitabine: effective oral fluoropyrimidine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinom

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

The assessment and management of cancer treatment-related diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Clinical pharmacokinetics of capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Autoregulation of 5-fluorouracil metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323001003800413

Relationship between fluorouracil systemic exposure and tumor response and patient survival

21 January 2018

5

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

28 July 2024

7

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Clinical and biochemical abnormalities in a patient with dihydropyrimidine dehydrogenase deficiency due to homozygosity for the C29R mutation

28 July 2024

12

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity

28 July 2024

14

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method

28 July 2024

15

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Dose and time dependencies of 5-fluorouracil pharmacokinetics

28 July 2024

23

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

28 July 2024

Cancer Treatment Reports

24

70

903

Erlichman C

1986

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Modified high-performance liquid chromatography assay for the measurement of 2'-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs.

28 July 2024

31

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Rapid, simple alkaline extraction of human genomic DNA from whole blood, buccal epithelial cells, semen and forensic stains for PCR

28 July 2024

32

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosa

28 July 2024

37

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Population study of dihydropyrimidine dehydrogenase in cancer patients

28 July 2024

42

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency

28 July 2024

46

1 reference

https://api.crossref.org/works/10.1177/147323001003800413

28 July 2024

Identifiers

1 reference

8 November 2017

1 reference